Skip to main content
. 2021 May 26;41(11):2944–2956. doi: 10.1177/0271678X211020587

Figure 2.

Figure 2.

The best diagnostic perfusion and permeability biomarkers of cavernous angioma with symptomatic hemorrhage (CASH) within a year prior to imaging. (a) Weighted βi coefficients of covariates in the perfusion biomarker of CASH (Bayesian information criterion [BIC]=414.9, McFadden R2=0.28); error bars are 95% confidence intervals (CI). (b) Canonical score of the perfusion biomarker was higher (p < 0.001) in CASH (median [interquartile range (IQR)]=0.28 [0.14–0.56]) than non-CASH lesions (0.04 [0.03–0.08]). (c) The perfusion biomarker had better efficacy in distinguishing CASH within a year prior to imaging (area under the curve (AUC) [95% CI]=86% [82–90%], p < 0.0001) than high-perfusion cluster area (73% [67–79%], p < 0.0001) and skewness individually (64% [57–71%], p < 0.0001). (d) Weighted βi (95% CI) coefficients of covariates in the permeability biomarker (BIC = 438.4, McFadden R2=0.25). (e) Canonical score of the permeability biomarker was higher (p < 0.001) in CASH (median [IQR]=0.29 [0.13–0.47]) than non-CASH lesions (0.04 [0.03–0.09]). (f) The permeability biomarker had better efficacy in distinguishing CASH within a year prior (AUC [95% CI]=84% [79–89%], p < 0.0001) than high-permeability cluster area (71% [65–77%], p < 0.0001), entropy (69% [63–75%], p < 0.0001), and skewness individually (56% [49–62%], p = 0.081). *** p < 0.001. AU: arbitrary unit.